At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 50 enrolled

Drug / intervention

Gefapixant +1 moredrug

Likely dose

Gefapixant 50 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02397460

NCT02397460Phase 2Completed

Compare CT.gov

A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Mar 25, 2015·Updated Feb 12, 2021

In Brief

A Phase 2 clinical trial evaluating Gefapixant and Placebo for Refractory Chronic Cough. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The primary objective of this double-blind crossover study is to assess the effect of single doses of 50 mg and 300 mg gefapixant (AF-219/MK-7264) on cough reflex sensitivity to capsaicin in both healthy participants and participants with chronic cough. This study will also assess the effect of single doses of gefapixant on cough reflex sensitivity to adenosine triphosphate (ATP) in healthy participants and participants with chronic cough.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsRefractory Chronic Cough

CountriesUnited Kingdom

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedMar 2015

Enrollment StartApr 2015

Primary CompletionApr 2016

Study CompletionMay 2016

TodayJul 2026

First PostedMar 25, 2015

Enrollment StartApr 29, 2015

Primary CompletionApr 22, 2016

Study CompletionMay 16, 2016

TodayJul 2, 2026

Enrollment to primary: 12 monthsPosted 11.3 years ago

Interventions

Gefapixantdrug

Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)

Placebodrug